Inmed Stock Analysis

INM
 Stock
  

USD 7.21  0.68  10.41%   

Inmed Pharmaceuticals price pull down over the last few months may raise some interest from stakeholders. The stock closed today at a share price of 7.21 on 153,637 in trading volume. The company executives were not very successful in positioning the firm resources to exploit market volatility in September. However, diversifying your holdings with Inmed Pharmaceuticals or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 13.51. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Inmed Pharmaceuticals partners.
Please see Risk vs Return Analysis.
  
The Inmed Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Inmed Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Inmed Stock analysis module also helps to analyze the Inmed Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Inmed Stock Analysis Notes

The book value of the company was currently reported as 1.47. The company recorded a loss per share of 1.37. Inmed Pharmaceuticals had not issued any dividends in recent years. The entity had 25.00 - 1.00 split on the 6th of July 2020. InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada. Inmed Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. To learn more about Inmed Pharmaceuticals call the company at 604 669 7207 or check out https://www.inmedpharma.com.

Inmed Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Inmed Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Inmed Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Inmed Pharmaceuticals generated a negative expected return over the last 90 days
Inmed Pharmaceuticals has high historical volatility and very poor performance
The company reported the last year's revenue of 574.68 K. Reported Net Loss for the year was (13.99 M) with profit before taxes, overhead, and interest of 543.55 K.
Inmed Pharmaceuticals has about 5.9 M in cash with (13.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.4.
Latest headline from www.investorsobserver.com: Where Does InMed Pharmaceuticals Inc Stock Fall in the Biotechnology Field After It Is Up 3738.46 percent This Week - InvestorsObserver

Inmed Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Inmed Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Inmed Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report10th of February 2022
Next Financial Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of September 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Inmed Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Inmed Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Inmed Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Inmed Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
13th of September 2022
Financial Statements and Exhibits. Other Events. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
8th of September 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
26th of August 2022
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure. Material Modifications to Rights of Security Holders
View
10th of August 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
26th of July 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
19th of July 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
15th of July 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
23rd of June 2022
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View

Inmed Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Inmed Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Inmed Pharmaceuticals backward and forwards among themselves. Inmed Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Inmed Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Armistice Capital LlcCommon Shares956.1 K450 K
Two Sigma Advisers LpCommon Shares48.3 K23 K
Renaissance Technologies LlcCommon Shares49.7 K23 K
Citadel Advisors LlcCommon Shares13 KK
Geode Capital Management LlcCommon Shares13.9 KK
Creative PlanningCommon Shares10.8 KK
National Bank Of CanadaCommon Shares1960.0
Note, although Inmed Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Inmed Market Capitalization

The company currently falls under 'Micro-Cap' category with total capitalization of 92.31 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Inmed Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Inmed Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has Return on Asset of (62.21) % which means that on every $100 spent on asset, it lost $62.21. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (131.34) %, meaning that it generated no profit with money invested by stockholders. Inmed Pharmaceuticals management efficiency ratios could be used to measure how well inmed pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 4th of October, Inmed Pharmaceuticals retains the risk adjusted performance of (0.00127), and Market Risk Adjusted Performance of (0.044416). Inmed Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Inmed Pharmaceuticals, which can be compared to its competitors. Please check out Inmed Pharmaceuticals coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Inmed Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 7.21 per share. Given that Inmed Pharmaceuticals has jensen alpha of 0.0307, we strongly advise you to confirm Inmed Pharmaceuticals's regular market performance to make sure the company can sustain itself at a future point.

Inmed Pharmaceuticals Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triangular Moving Average shows Inmed Pharmaceuticals double smoothed mean price over a specified number of previous prices (i.e., averaged twice).
.

Inmed Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inmed Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inmed Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Inmed Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lemerond Nicole over a month ago via Macroaxis 
Acquisition by Lemerond Nicole of 14000 shares of Inmed Pharmaceuticals subject to Rule 16b-3
Mancini Alexandra Diane Janet over three months ago via Macroaxis 
Expiration or cancellation by Mancini Alexandra Diane Janet of long derivative position of 1515 shares of Inmed Pharmaceuticals
Baldasare Bryan T over three months ago via Macroaxis 
Acquisition by Baldasare Bryan T of 14000 shares of Inmed Pharmaceuticals subject to Rule 16b-3
Adams Eric A over three months ago via Macroaxis 
Purchase by Adams Eric A of 14160 shares of Inmed Pharmaceuticals
Adams Eric A over three months ago via Macroaxis 
Purchase by Adams Eric A of 8560 shares of Inmed Pharmaceuticals
Woudenberg Michael over six months ago via Macroaxis 
Acquisition by Woudenberg Michael of 5000 shares of Inmed Pharmaceuticals subject to Rule 16b-3
Mancini Alexandra Diane Janet over six months ago via Macroaxis 
Expiration or cancellation by Mancini Alexandra Diane Janet of long derivative position of 3030 shares of Inmed Pharmaceuticals
Grove Janet P over six months ago via Macroaxis 
Acquisition by Grove Janet P of 14000 shares of Inmed Pharmaceuticals subject to Rule 16b-3
Hull Andrew over six months ago via Macroaxis 
Expiration or cancellation by Hull Andrew of long derivative position of 30303 shares of Inmed Pharmaceuticals
Johnson Shane Aaron over six months ago via Macroaxis 
Purchase by Johnson Shane Aaron of 8500 shares of Inmed Pharmaceuticals
Johnson Shane Aaron over six months ago via Macroaxis 
Purchase by Johnson Shane Aaron of 8093 shares of Inmed Pharmaceuticals
Johnson Shane Aaron over six months ago via Macroaxis 
Purchase by Johnson Shane Aaron of 5000 shares of Inmed Pharmaceuticals

Inmed Pharmaceuticals Predictive Daily Indicators

Inmed Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Inmed Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Inmed Pharmaceuticals Forecast Models

Inmed Pharmaceuticals time-series forecasting models is one of many Inmed Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Inmed Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Inmed Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Inmed Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Inmed shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Inmed Pharmaceuticals. By using and applying Inmed Stock analysis, traders can create a robust methodology for identifying Inmed entry and exit points for their positions.
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada. Inmed Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.

Current Inmed Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Inmed analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Inmed analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
6.75Strong Buy2Odds
Inmed Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Inmed analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Inmed stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Inmed Pharmaceuticals, talking to its executives and customers, or listening to Inmed conference calls.
Inmed Analyst Advice Details

Inmed Stock Analysis Indicators

Inmed Pharmaceuticals stock analysis indicators help investors evaluate how Inmed Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Inmed Pharmaceuticals shares will generate the highest return on investment. By understating and applying Inmed Pharmaceuticals stock analysis, traders can identify Inmed Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio1.45
Fifty Two Week Low4.95
Shares Short Prior Month102.31k
Average Daily Volume Last 10 Day1.7M
Average Daily Volume In Three Month914.09k
Shares Percent Shares Out0.13%
Gross Margins51.13%
Short Percent Of Float0.13%
Forward Price Earnings-13.33
Float Shares14.36M
Fifty Two Week High59.25
Enterprise Value To Ebitda-0.05
Fifty Day Average8.71
Two Hundred Day Average18.99
Enterprise Value To Revenue1.28
Please see Risk vs Return Analysis. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for analysis

When running Inmed Pharmaceuticals price analysis, check to measure Inmed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmed Pharmaceuticals is operating at the current time. Most of Inmed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Inmed Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Inmed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Is Inmed Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inmed Pharmaceuticals. If investors know Inmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Inmed Pharmaceuticals is measured differently than its book value, which is the value of Inmed that is recorded on the company's balance sheet. Investors also form their own opinion of Inmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Inmed Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.